Rigel Pharmaceuticals Inc

Rigel insider trading reveals cautious optimism: CEO sells while other executives buy, amid strong pipeline data on sotigalimab and HG‑102 gene‑editing, hinting at upcoming regulatory approvals and investor confidence.

Insider buying at Rigel signals confidence in its rare‑disease pipeline, hinting at future reimbursement and tech‑driven adoption in healthcare systems.

Insider trades at Rigel Pharma reveal portfolio moves, not panic—executives’ actions amid a dip in shares, yet confidence stays high as Q3 2026 clinical data approaches.